Table 1.
Median Change Relative to Pretreatment in Bone Markers after Cycle 1 of Zoledronic Acid or Docetaxel/Estramustine
| |
Zoledronic acid |
Docetaxel/estramustine |
|
||
|---|---|---|---|---|---|
| Bone markera | Number | Median (range) | Number | Median (range) | p value |
| BAP | 13 | −0.04 (−0.33, 1.31) | 13 | −0.15 (−0.59, 0.47) | 0.58 |
| DpD | 12 | 0.40 (−0.97, 35.4) | 13 | 0.0 (−0.98, 20.7) | 0.81 |
| IL-6 | 13 | −0.12 (−12.2, 4.2) | 13 | 0.15 (−0.83, 3.5) | 0.51 |
| OCN | 13 | −0.16 (−0.43, 63.4) | 13 | −0.43 (−0.68, 1.05) | 0.11 |
| OPG | 13 | 0.10 (−0.38, 0.64) | 12 | 0.06 (−0.48, 1.44) | 0.73 |
| TRAPC | 13 | −0.46 (−1.0, 0.25) | 13 | −0.39 (−1.1, 2.0) | 0.27 |
| RANKL* | 13 | −0.004 (−0.21, 8.0) | 13 | −0.01 (−0.19, 1.31) | 0.76 |
| PSA | 13 | 0.0 (−0.84, 2.1) | 13 | −0.28 (−0.77, 0.09) | 0.01 |
a
Interleukin-6 (IL-6), urinary deoxypyridinoline to serum creatinine ratio (DpD), tartrate-resistant acid phosphatase (TRAPC), bone-specific alkaline phosphatase (BAP), intact osteocalcin (OCN), and osteoprotegerin (OPG), ligand for receptor activator of nuclear-factor κB (RANKL), prostate-specific antigen (PSA). *Values represent actual difference rather than relative difference.